中國上海和美國馬薩諸塞州劍橋市2026年11月14日 /美通社/ -- 再鼎醫藥有限公司（納斯達克股票代碼：ZLAB；香港聯交所股份代號：9688），一家以創新為驅動的全球生物製藥公司，今日宣布，公司在國內的多款商業化產品被納入《國家基本醫療保險、生育保險和工傷保險藥品目錄（2026）》。本次更新包括兩款首次納入產品，擴大了全身型重症肌無力（gMG）患者與精神分裂症治療患者的治療可及性；以及三款續約產品，持續保障了腫瘤和感染性疾病領域的用藥可及性。

再鼎醫藥本次新增或續約納入2026版醫保藥品目錄的產品：

首次納入：

• 艾加莫德α注射液（皮下注射）（衛力迦^®）：用於治療乙酰膽鹼受體（AChR）抗體陽性的成人全身型重症肌無力（gMG）患者。
• 呫諾美林曲司氯銨膠囊(I)/(II)/(III)（凱捷樂^®）：用於治療成人精神分裂症。

續約產品：

• 注射用甲苯磺酸奧馬環素（紐再樂^®）：用於治療社區獲得性細菌性肺炎和急性細菌性皮膚和皮膚結構感染。
• 瑞派替尼片（擎樂^®）：用於治療既往接受過3種或以上激酶抑製劑（包括伊馬替尼）的晚期胃腸間質瘤（GIST）成人患者。
• 瑞普替尼膠囊（奧凱樂^®）：用於治療ROS1陽性的局部晚期或轉移性非小細胞肺癌（NSCLC）成人患者，以及攜帶神經營養酪氨酸受體激酶（NTRK）融合基因的成人實體瘤患者。

「呫諾美林曲司氯銨膠囊與艾加莫德α注射液（皮下注射）成功納入國家醫保藥品目錄，對再鼎以及我們所服務的患者而言，是一個重要的里程碑，」再鼎醫藥運營合伙人王軼喆博士表示，「這將有助於擴大兩款重要療法的可及性——包括呫諾美林曲司氯銨膠囊用於精神分裂症的創新作用機制，以及艾加莫德α注射液（皮下注射）為全身型重症肌無力患者帶來的給葯便利。連同其他已上市產品的成功續約，我們衷心感謝國家醫保局對創新藥物的持續支持，並將繼續致力於為患者帶來更大獲益。」

2026年版國家醫保藥品目錄將於2027年1月1日起執行。

關於再鼎醫藥

再鼎醫藥（納斯達克股票代碼：ZLAB；香港聯交所股份代號：9688）是一家以研發為基礎、處於商業化階段的創新型生物製藥公司，總部位於中國和美國。我們致力於通過創新產品的發現、開發和商業化解決腫瘤、免疫、神經科學和感染性疾病領域未被滿足的巨大醫療需求。我們的目標是利用我們的能力和資源為人類健康帶來積極影響。

有關再鼎醫藥的更多信息，請訪問 www.zailaboratory.com 或關注公司官微：再鼎醫藥。

再鼎醫藥前瞻性聲明

本新聞稿包含關於我們對再鼎醫藥未來預期、計劃以及前景的前瞻性陳述，包括但不限於有關艾加莫德皮下注射、呫諾美林曲司氯銨、瑞派替尼、瑞普替尼和甲苯磺酸奧馬環素的獲益與潛力，以及在中國治療全身型重症肌無力（gMG）、精神分裂症、非小細胞肺癌（NSCLC）、某些實體瘤、社區獲得性細菌性肺炎和急性細菌性皮膚和皮膚結構感染的陳述。除對過往事實的陳述外，本新聞稿中包含的所有陳述均為前瞻性陳述，可以通過諸如「旨在」、「預計」、「認為」、「有可能」、「估計」、「預期」、「預測」、「目標」、「打算」、「可能」、「計劃」、「可能的」、「潛在」、「將」、「將會」等詞彙及其他類似表述加以識別。前瞻性陳述並非對未來表現的承諾或保證，乃基於我們截至本新聞稿發布之日的預期和假設，並且受固有的不確定性、風險及可能與前瞻性陳述所預期的情況存在重大差異的情勢變更的影響。實際結果可能受各多種重要因素的影響存在重大差異，該等因素包括但不限於：(1) 我們成功商業化已獲批產品並從中產生收入的能力；(2) 我們為運營和業務活動獲取資金的能力；(3) 我們候選產品臨床及臨床前開發的結果；(4) 相關監管機構對我們候選產品作出審批決定的內容和時間；(5) 與在中國營商有關的風險；以及 (6) 我們向美國證券交易委員會（SEC）提交的最新年報和季報及其他報告中指出的其他因素。除法律要求之外，無論出於新信息、未來事件或其他原因，我們均無義務更新或修訂任何前瞻性陳述。如需查閱公司向 SEC 提交的文件，請訪問公司網站 www.zailaboratory.com 和 SEC 網站 www.SEC.gov。

SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease.

Zai Lab Products Newly Added or Renewed in 2026 NRDL:

First-time listings:

• VYVGART Hytrulo^® (efgartigimod alfa, subcutaneous injection): for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).
• KarXT (xanomeline and trospium chloride capsules): for the treatment of schizophrenia in adults.

Renewals:

• NUZYRA^® (omadacycline for injection): for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
• QINLOCK^® (ripretinib tablets): for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
• AUGTYRO^® (repotrectinib capsules): for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), and adult patients with solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

"The inclusion of KarXT and VYVGART Hytrulo in the NRDL represents an important milestone for Zai Lab and the patients we serve," said Dr. Yizhe Wang, Zai Lab Operating Partner. "These listings will help broaden access to two important therapies, including KarXT's novel mechanism of action for schizophrenia and the convenience of VYVGART Hytrulo's subcutaneous administration for patients with gMG. Together with the renewal of our other listed products, we are grateful to the National Healthcare Security Administration for its continued support of innovative medicines and remain committed to delivering greater benefit to patients."

The 2026 National Reimbursement Drug List will take effect on January 1, 2027.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.linkedin.com/company/zai-lab or https://x.com/ZaiLab_Global.

Zai Lab Forward-Looking Statements

This press release contains forward-looking statements about our future expectations, plans, and prospects for Zai Lab, including, without limitation, statements relating to the benefits and potential of VYVGART Hytrulo, KarXT, QINLOCK, AUGTYRO, and NUZYRA and the treatment of gMG, schizophrenia, NSCLC, certain solid tumors, and community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in China. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and can be identified by terms such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "will," "would," and similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither promises nor guarantees of future performance, and are based on our expectations and assumptions as of the date of this press release, and are subject to inherent uncertainties, risks, and changes in circumstances that may cause actual results to differ materially from those anticipated. Actual results may differ materially as a result of various important factors, including but not limited to: (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business activities; (3) the results of clinical and preclinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. For access to the company's filings with the SEC, please visit www.zailaboratory.com and the SEC's website at www.SEC.gov.

PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced that seven innovative products of Innovent were successfully included in the updated National Reimbursement Drug List (2026) (the "NRDL").

Products included in the NRDL for the first time include mazdutide (a GCG/GLP-1 dual receptor agonist), PECONDLE® (picankibart injection, an IL-23p19 inhibitor), TABOSUN® (Ipilimumab N01 injection, a CTLA-4 inhibitor), and Vanflyta® (quizartinib, a Type II FLT3 inhibitor). Products with newly added indications included in the NRDL comprise TYVYT® (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jaypirca® (pirtobrutinib, a non-covalent BTK inhibitor); and SINTBILO® (tafolecimab injection, a fully human PCSK9 monoclonal antibody) was successfully renewed. The updated NRDL will officially take effect from January 1, 2027.

Dr. Michael Yu, the Founder, Chairman of the Board and CEO of Innovent, stated: "We are highly pleased that the seven innovative drugs of Innovent have been successfully included in the National Reimbursement Drug List this time, covering disease areas with heavy societal burdens such as oncology (colon cancer, renal cancer, and hematological malignancies), cardiovascular and metabolic diseases, as well as autoimmune diseases. The inclusion of the innovative drugs in the NRDL will further enhance the accessibility and affordability for patients, allowing more of the public to benefit. With this, the lineup of Innovent's innovative drugs covered by the NRDL has expanded to 17, cumulatively benefiting over 20 million patients, and continuously fortifying the medication safeguards for patients through innovative achievements. Adhering to our corporate mission to 'empower patients worldwide with affordable, high-quality biopharmaceuticals', Innovent consistently places patient needs at its core, actively responds to the strategic call of 'Healthy China 2030', facilitates the construction of a universal health safeguard system through practical actions, and promotes the continuous improvement of people's health. We will actively cooperate with the implementation of medical insurance policies, ensuring that high-quality innovative medicines benefit countless households faster and more broadly.

Mazdutide
Innovent entered into an exclusive license agreement with Eli Lilly and Company for the development and commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.

Mazdutide is newly included in the updated NRDL for: type 2 diabetes in adults. Mazdutide is the first and only approved GCG/GLP-1 dual receptor agonist globally. This inclusion into the NRDL will provide a better option for the comprehensive management of Chinese patients with type 2 diabetes.

PECONDLE® (picankibart injection)

Picankibart (IBI112) is a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody injection. It is a monoclonal antibody with independent intellectual property rights independently developed by Innovent, which specifically binds to the IL-23p19 subunit. By preventing IL-23 from binding to cell surface receptors, it blocks the IL-23 receptor-mediated signaling pathway to exert anti-inflammatory effects.

Picankibart injection is newly included in the updated NRDL for: adult patients with moderate to severe plaque psoriasis eligible for systemic therapy. Picankibart is the first and only domestic IL-23p19 inhibitor. It is also the first product among global IL-23p19 drugs with the same target to achieve a PASI 90 response rate exceeding 80% at 16 weeks in a Phase III registrational clinical trial, and possesses the longest maintenance dosing interval in its class (once every 12 weeks). This inclusion in the NRDL will effectively improve treatment convenience and patient compliance.

TABOSUN® (Ipilimumab N01 injection)

Ipilimumab N01 (IBI310) is a recombinant fully human anti-CTLA-4 monoclonal antibody independently developed by Innovent. Ipilimumab N01 can specifically bind to CTLA-4, thereby blocking CTLA-4-mediated T cell inhibition, promoting the activation and proliferation of T cells, enhancing the tumor immune response, and achieving anti-tumor effects.

Ipilimumab N01 injection is newly included in the updated NRDL for: use in combination with sintilimab for the neoadjuvant treatment of patients with resectable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer. As the world's only approved dual-immunotherapy combination regimen for this indication, it synergistically activates anti-tumor immunity through both the CTLA-4 and PD-1 pathways, providing patients with a short-course, chemotherapy-free, and 0-recurrence neoadjuvant treatment option, which fills the dual gaps in clinical practice and medical insurance coverage.

VANFLYTA® (quizartinib)

Quizartinib is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations, developed by Daiichi Sankyo and solely commercialized in Mainland China by Innovent.

Quizartinib is newly included in the updated NRDL for: newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive as detected by an adequate validated diagnostic test. It has effectively filled the gap in the NRDL coverage, addressed the shortcomings in clinical treatment, and practically alleviated the treatment burden of AML patients.

TYVYT® (sintilimab injection)

Sintilimab injection (IBI308) is an innovative PD-1 inhibitor drug jointly developed by Innovent and Eli Lilly and Company.

Sintilimab has been approved in China for ten indications, covering squamous non-small cell lung cancer, non-squamous non-small cell lung cancer (including EGFR/ALK wild type non-squamous NSCLC and EGFR-TKI treatment failed non-squamous NSCLC), hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin's lymphoma.

Two additional indications have been successfully included in the updated NRDL: sintilimab in combination with ipilimumab N01 as neoadjuvant treatment for patients with resectable stage IIB–III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer; and sintilimab in combination with fruquintinib for patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) therapy and have not received programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy in the first-line setting. The NRDL inclusion of two indications further broadens reimbursement coverage for the neoadjuvant treatment of patients with MSI-H/dMMR colon cancer and the combination treatment of targeted therapy and immunotherapy for second-line renal cell carcinoma patients.

Jaypirca® (pirtobrutinib)

Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly and Company, for which Innovent is responsible for the exclusive commercialization in Mainland China. In preclinical studies, pirtobrutinib is 300 times more selective for BTK versus 98% of other kinases tested^[i]. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)^[ii],[iii].

Pirtobrutinib was approved in China in October 2024 and was officially included in the NRDL on January 1, 2026. One additional indication has now been successfully included in the updated NRDL: treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior systemic therapy that included a Bruton's tyrosine kinase (BTK) inhibitor. This further broadens NRDL coverage for the treatment of this disease.

SINTBILO® (tafolecimab injection)

Tafolecimab injection (IBI306) is the first domestic fully human anti-PCSK9 monoclonal antibody independently developed by Innovent. By inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) in blood plasma, it blocks its binding to the low-density lipoprotein receptor(LDLR), thereby preventing the endocytosis and degradation of LDLR, increasing the expression level and quantity of LDLR on the cell surface, enhancing the reuptake of low-density lipoprotein cholesterol (LDL-C) by LDLR, and decreasing the circulating LDL-C level, ultimately achieving the purpose of lowering blood lipids.

Tafolecimab was approved for marketing in August 2023 and was officially included in the NRDL on January 1, 2025. This successful contract renewal will further alleviate the financial burden on patients, enabling this advanced lipid-lowering therapy to benefit a broader patient population.

Looking towards the goals of the China's "15th Five-Year Plan", Innovent will remain committed to innovation-driven development, focus on the unmet clinical needs in the field of major diseases, and continuously advance the R&D, manufacturing and commercialization of high-quality innovative drugs, to serve people's lives and health with more innovative achievements, and contribute to the high-quality development of the biopharmaceutical industry and the building of a "Healthy China".

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 6 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high quality outbound internationalization of China's innovative drug industry.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

References

Adjusted Profit Attributable to Owners of the Parent Surges 54.5% Year-on-Year to HK$2.24 Billion

Global Business Continues to Grow, with Strong Operating Performance in International Markets

Results Highlights

• TCL Electronics firmly implemented its dual-drive strategy of "Globalisation" and "Mid-to-High-End Premiumisation", achieving strong growth in operating performance. For the first three quarters of 2026, the Group recorded total revenue of HK$95.79 billion, representing a year-on-year increase of 15.7%. Adjusted profit attributable to owners of the parent increased by 54.5% year-on-year to HK$2.24 billion.
• Display Business: For the first three quarters of 2026, revenue from the Display Business increased by 19.1% year-on-year to HK$62.38 billion, while gross profit increased by 38.4% year-on-year to HK$11.51 billion. Further product mix optimisation in international markets continued to enhance profitability. In particular, international shipments of TCL Mini LED TVs recorded rapid year-on-year growth of 94.5%, driving a 4.4-percentage-point year-on-year increase in the gross profit margin of the Large-Sized Display business in international markets to 19.0%.
• Internet Business: For the first three quarters of 2026, revenue from the Internet Business increased by 28.2% year-on-year to HK$2.70 billion. The proportion of the higher-margin international internet business with its share of total Internet Business revenue increased to over 50%. This drove a 4.6-percentage-point year-on-year increase in the overall gross profit margin of the Internet Business to 60.9%, continuing to contribute high-quality earnings.
• Innovative Business: For the first three quarters of 2026, revenue from the Innovative Business increased by 8.5% year-on-year to HK$30.68 billion. Among its businesses, the Photovoltaic Business maintained resilient growth amid industry headwinds, with revenue increasing by 11.8% year-on-year to HK$18.18 billion.
• Strategic Development: The Company acquired the TCL air-conditioning business for a total consideration of HK$5.61 billion. The transaction was completed on 2 November 2026, and the acquired business was consolidated into the Company's financial statements, marking a significant step towards the comprehensive implementation of its "All-category Smart Device" strategy.

HONG KONG, Nov. 13, 2026 /PRNewswire/ -- TCL Electronics Holdings Limited ("TCL Electronics" or the "Company", 01070.HK) today announced its unaudited results for the first three quarters of 2026, covering the nine months ended 30 September 2026. During the reporting period, the Company firmly implemented its dual-drive strategy of "Globalisation" and "Mid-to-High-End Premiumisation" and actively deepened cooperation with global channels, achieving strong growth in operating performance. For the first three quarters of 2026, the Company recorded total revenue of HK$95.79 billion, representing a year-on-year increase of 15.7%. Gross profit increased by 29.5% year-on-year to HK$16.26 billion, while gross profit margin increased by 1.8 percentage points year-on-year to 17.0%. The overall expense^[1] ratio was 11.9%. Driven by both improved operating efficiency and the realisation of economies of scale, adjusted profit attributable to owners of the parent increased by 54.5% year-on-year to HK$2.24 billion.

In terms of strategic development, the Company continued to advance industrial synergies, the integration of core assets and the optimisation of its business structure. On 31 March 2026 (after trading hours), the Company entered into a transaction framework agreement with Sony in relation to the home entertainment business. The two parties proposed to establish a joint venture to jointly build a new global home entertainment ecosystem, providing important strategic support for the expansion into the mid-to-high-end market. In addition, on 15 July 2026 (after trading hours), the Company announced its proposed acquisition of the TCL air-conditioning business for a total consideration of HK$5.61 billion. The transaction was completed on 2 November 2026, and the relevant business has been consolidated into the Company's financial statements since the completion date, laying an important foundation for the Company to comprehensively implement its "All-category Smart Device" strategy. On 24 August 2026, the Company announced that it was considering the spin-off and separate listing of its photovoltaic business through a distribution in specie. The Company will comprehensively and prudently evaluate the various impacts of implementing this proposal from the perspective of maximising the interests of all shareholders. Looking ahead to the full year of 2026, the Company is confident that it will achieve sustained and steady growth through firm execution of its strategies.

Continued Enhancement of Global Brand Strength, with Significant Improvements in Profitability of Mid-to-High-End and Large-Sized TVs in International Markets

Underpinned by continued enhancement of its global brand strength, efficient channel expansion and ongoing product mix optimisation, the Company's Display Business recorded revenue of HK$62.38 billion, representing a year-on-year increase of 19.1%, and gross profit of HK$11.51 billion, representing a year-on-year increase of 38.4%. Gross profit margin increased by 2.6 percentage points year-on-year to 18.5%. Benefitting from the continued increase in the proportion of mid-to-high-end and large-sized TVs, revenue from the TCL TV business increased by 16.7% year-on-year to HK$52.03 billion, while gross profit margin increased by 3.2 percentage points year-on-year to 19.5%.

TCL Mini LED TVs maintained rapid growth for the first three quarters of 2026, with global shipments increasing by 57.9% year-on-year and their share of total shipments rising by 6.1 percentage points year-on-year to 17.5%. In particular, shipments in international markets increased by 94.5% year-on-year, driving a 4.4-percentage-point year-on-year increase in the gross profit margin of the TV business in international markets to 19.0%. The Company continued to expand its global channel footprint and deepen the development of key channels. These efforts helped TCL TV rank among the top three globally in sales revenue, maintain its second-place ranking globally in shipment volume, and retain its position as the world's No. 1 brand in TCL Mini LED TV shipments^[2]. TCL X11L SQD-Mini LED TV was named one of TIME magazine's "Best Inventions of 2026" in the United States, making it the only Chinese television product selected in this category and further demonstrating the Company's leading position in premium display technology.

In the Small-and-Medium-Sized Display business, the Company adhered to the strategy of "prioritising efficiency and focusing on key markets" and continued to deepen its presence in key channels in Europe and the United States. Leveraging differentiated products such as NXTPAPER eye-care display technology, the business achieved growth against the market trend, with both revenue and gross profit outperforming the industry as a whole. For the first three quarters of 2026, revenue from the Small-and-Medium-Sized Display business increased by 32.2% year-on-year to HK$9.32 billion.

International Internet Business Contributes to High-Quality Earnings, While Photovoltaic Business Achieves Substantive Progress in the European Market

During the Reporting Period, the Company's Internet Business recorded revenue of HK$2.70 billion, representing a year-on-year increase of 28.2%. Among its businesses, the expansion of the higher-margin international internet business continued to accelerate, with its share of Internet Business revenue increasing by 17.0 percentage points year-on-year. This drove a 4.6-percentage-point year-on-year increase in the overall gross profit margin of the Internet Business to 60.9%, continuing to contribute high-quality earnings. In international markets, leveraging its scale advantages, the Company continued to deepen cooperation with internet giants such as Google, Roku and Netflix. The content application TCL Channel continued to undergo iterative upgrades in terms of content richness, user experience and monetisation efficiency. As at the end of September 2026, TCL Channel had a cumulative user base of 56.99 million.

In the Innovative Business, for the first three quarters of 2026, the Company recorded revenue of HK$30.68 billion, representing a year-on-year increase of 8.5%. Among its businesses, the Photovoltaic Business maintained resilient growth amid industry headwinds, with revenue increasing by 11.8% year-on-year to HK$18.18 billion. The business focused on key countries in Europe in international markets and made substantive progress in advancing integrated energy solutions combining photovoltaics, energy storage and heating, leveraging the brand influence of SunPower.

For the first three quarters of 2026, the Company continued to promote the synergistic development of its All-Category Marketing business and improve the layout of its smart device product portfolio. Revenue increased by 3.3% year-on-year to HK$10.95 billion. Meanwhile, in August 2026, the Company launched TCL AiMe, an AI companion and caregiving robot, further enriching its all-scenario smart ecosystem and opening up new growth opportunities in the emerging consumer electronics sector.

-     Ends     -

About TCL Electronics

TCL Electronics Holdings Limited (01070.HK, incorporated in the Cayman Islands with limited liability) has been listed on the Main Board of The Stock Exchange of Hong Kong Limited since November 1999. Its business scope covers display business, innovative business, and internet business. Guided by the business philosophy of "Strategy Guidance, Innovation Driven, Advanced Manufacturing and Global Operation", TCL Electronics actively embraces transformation and innovation and focuses on breaking into the mid-to high-end global market, and strives for an all-category layout for the "Smart IoT Ecosystem". Dedicated to providing users with all-scenario smart healthy living experiences, TCL Electronics aims to become a leading global intelligent terminal enterprise. TCL Electronics is included in the list of eligible shares for the Shenzhen-Hong Kong Stock Connect. It is a constituent stock of the Hang Seng Stock Connect Hong Kong Index, the Hang Seng Composite LargeCap & MidCap Index, the Hang Seng Composite MidCap Index and the "Hang Seng SCHK Electronics Theme Index". Since 2018, the Company has been awarded an ESG rating of A by Hang Seng Indexes Company for several consecutive years.

For more information, please visit TCL Electronics' investor relations website at http://electronics.tcl.com.

經調整歸母淨利潤同比升54.5%至22.4億港元

全球業務規模增長持續 國際市場經營業績表現強勁

業績亮點

• TCL電子堅定落實「全球化」與「中高端化」雙輪驅動戰略，經營業績實現強勁增長。2026年首三季度收入同比增長15.7%至957.9億港元，經調整歸母淨利潤同比增長54.5%至22.4億港元。
• 顯示業務：2026年首三季度，顯示業務收入同比增長19.1%至623.8億港元，毛利同比增長38.4%至115.1億港元。國際市場產品結構優化進一步提升盈利能力，其中TCL Mini LED TV國際市場出貨量錄高速同比增長達94.5%，帶動大呎吋顯示業務國際市場毛利率同比提升4.4個百分點至19.0%。
• 互聯網業務：2026年首三季度，互聯網業務收入同比增長28.2%至27.0億港元，其中更高毛利的國際互聯網業務佔整體互聯網業務收入比重超五成，帶動互聯網業務整體毛利率同比增長4.6個百分點至60.9%，持續貢獻高質量盈利。
• 創新業務：2026年首三季度，創新業務收入同比增長8.5%至306.8億港元。其中，光伏業務在行業逆風中保持韌性增長，收入同比增長11.8%至181.8億港元。
• 戰略發展：公司以總代價56.1億港元收購TCL空調業務，於2026年11月2日完成交割並納入公司合併財務報表，全面推進「全品類智能終端」佈局。

香港2026年11月13日 /美通社/ -- TCL電子控股有限公司（「TCL電子」或「公司」，01070.HK）今天公佈截至2026年9月30日首三季度未經審核業績。報告期內，公司堅定落實「全球化」與「中高端化」雙輪驅動戰略，積極深化全球渠道合作，經營業績實現強勁增長。2026年首三季度，公司實現總收入957.9億港元，較去年同期增長15.7%。毛利實現同比增長29.5%至162.6億港元，毛利率同比提升1.8個百分點至17.0%；整體費用^[1]率為11.9%；在運營效率提升及規模效應顯現的雙重推動下，經調整歸母淨利潤同比增長54.5%至22.4億港元。 

戰略發展方面，公司持續推進產業協同佈局、核心資產整合與業務架構優化。於2026年3月31日（交易時段後）與索尼就家庭娛樂領域簽訂交易框架協議，雙方擬設立合資公司，共建全球家庭娛樂新生態，為拓展中高端市場帶來重要戰略支撐。此外，2026年7月15日（交易時段後），公司宣佈擬以總代價56.1億港元收購TCL空調業務，該交易於2026年11月2日完成交割，相關業務自交割日起納入公司合併財務報表，為公司全面推進「全品類智能終端」佈局墊下重要基礎。2026年8月24日，公司公告正考慮透過實物分派方式分立光伏業務並獨立上市，公司將從全體股東利益最大化的角度，全面審慎評估落實該方案帶來的各項影響。展望2026年全年，公司有信心透過堅定的戰略執行，實現持續的穩健增長。

全球品牌力持續提升，國際市場中高端及大呎吋TV盈利能力大幅提升

依託全球品牌力持續提升、渠道高效拓展及產品結構不斷優化，公司顯示業務收入同比增長19.1%至623.8億港元，毛利同比增長38.4%至115.1億港元，毛利率同比提升2.6個百分點至18.5%。受益於中高端及大呎吋TV佔比持續提升，TCL TV業務收入同比增長16.7%至520.3億港元，毛利率同比提升3.2個百分點至19.5%。

TCL Mini LED TV維持高速增長，2026年首三季度全球出貨量同比增長57.9%，出貨量佔比同比上升6.1個百分點至17.5%；其中國際市場出貨量同比增長94.5%，帶動TV業務國際市場毛利率同比提升4.4個百分點至19.0%。公司繼續擴大全球渠道佈局並深化重點渠道發展，推動TCL TV全球銷售額排名全球前三，出貨量排名保持全球第二，TCL Mini LED TV出貨量穩居全球第一位^[2]。TCL X11L SQD-Mini LED TV入選美國《時代》週刊「2026 年度最佳發明」，為該類別中唯一入選的中國電視產品，進一步印證公司在高端顯示技術領域的領先地位。

中小呎吋顯示業務方面，公司堅持「效益優先、聚焦重點市場」策略，深耕歐美重點渠道，憑藉NXTPAPER護眼顯示等差異化產品實現逆勢增長，收入與毛利表現均優於行業整體；2026年首三季度，中小呎吋顯示業務收入同比增長32.2%至93.2億港元。

國際互聯網業務貢獻高質量盈利，光伏業務歐洲市場取得實質性進展

2026年首三季度，公司互聯網業務收入同比增長28.2%至27.0億港元。其中，更高毛利的國際互聯網業務擴張持續加速，其收入佔互聯網業務收入的佔比同比提升17.0個百分點，帶動互聯網業務整體毛利率同比增長4.6個百分點至60.9%，持續貢獻高質量盈利。國際市場方面，公司憑藉規模優勢，持續深化與Google、Roku及Netflix等互聯網巨頭合作，內容聚合應用TCL Channel在內容豐富度、用戶體驗及變現效率方面持續迭代升級。截至2026年9月底，TCL Channel累計用戶達5,699萬。

創新業務方面，2026年首三季度收入同比增長8.5%至306.8億港元。其中，光伏業務在行業逆風中保持韌性增長，收入同比增長11.8%至181.8億港元。國際市場聚焦歐洲重點國家，依託SunPower品牌影響力推進光伏、儲能及供熱一體化綜合能源解決方案，取得實質性進展。

2026年首三季度，公司持續推進全品類營銷業務的協同發展，完善智能終端產品矩陣佈局，收入同比增長3.3%至109.5億港元。同時，公司於2026年8月推出AI陪育機器人TCL AiMe，進一步豐富全場景智能生態佈局，在新興消費電子賽道打開新的增長空間。

有關TCL電子

TCL電子控股有限公司（01070.HK，於開曼群島註冊成立之有限公司），自1999年11月起於香港聯交所主板上市，業務範圍涵蓋顯示業務、創新業務以及互聯網業務。TCL電子以「戰略引領、創新驅動、先進製造、全球經營」為經營理念，積極變革創新，聚焦突破全球中高端市場，努力夯實「智能物聯生態」全品類佈局，致力為用戶提供全場景智慧健康生活，致力成為全球化經營的領先智能終端企業。TCL電子已獲納入深港通之合資格港股通股份名單，是恒生港股通指數、恒生綜合中大型股指數、恒生綜合中型股指數基準指數及恒生港股通電子主題指數成分股，並從2018年起連續多年獲得恒生指數公司授予ESG評級A。

如欲查詢更多資料，請瀏覽TCL電子投資者關係網站 http://electronics.tcl.com。

Adjusted Profit Attributable to Owners of the Parent Surges 54.5% Year-on-Year to HK$2.24 Billion

Global Business Continues to Grow, with Strong Operating Performance in International Markets

Results Highlights

• TCL Electronics firmly implemented its dual-drive strategy of "Globalisation" and "Mid-to-High-End Premiumisation", achieving strong growth in operating performance. For the first three quarters of 2026, the Group recorded total revenue of HK$95.79 billion, representing a year-on-year increase of 15.7%. Adjusted profit attributable to owners of the parent increased by 54.5% year-on-year to HK$2.24 billion.
• Display Business: For the first three quarters of 2026, revenue from the Display Business increased by 19.1% year-on-year to HK$62.38 billion, while gross profit increased by 38.4% year-on-year to HK$11.51 billion. Further product mix optimisation in international markets continued to enhance profitability. In particular, international shipments of TCL Mini LED TVs recorded rapid year-on-year growth of 94.5%, driving a 4.4-percentage-point year-on-year increase in the gross profit margin of the Large-Sized Display business in international markets to 19.0%.
• Internet Business: For the first three quarters of 2026, revenue from the Internet Business increased by 28.2% year-on-year to HK$2.70 billion. The proportion of the higher-margin international internet business with its share of total Internet Business revenue increased to over 50%. This drove a 4.6-percentage-point year-on-year increase in the overall gross profit margin of the Internet Business to 60.9%, continuing to contribute high-quality earnings.
• Innovative Business: For the first three quarters of 2026, revenue from the Innovative Business increased by 8.5% year-on-year to HK$30.68 billion. Among its businesses, the Photovoltaic Business maintained resilient growth amid industry headwinds, with revenue increasing by 11.8% year-on-year to HK$18.18 billion.
• Strategic Development: The Company acquired the TCL air-conditioning business for a total consideration of HK$5.61 billion. The transaction was completed on 2 November 2026, and the acquired business was consolidated into the Company's financial statements, marking a significant step towards the comprehensive implementation of its "All-category Smart Device" strategy.

HONG KONG, Nov. 13, 2026 /PRNewswire/ -- TCL Electronics Holdings Limited ("TCL Electronics" or the "Company", 01070.HK) today announced its unaudited results for the first three quarters of 2026, covering the nine months ended 30 September 2026. During the reporting period, the Company firmly implemented its dual-drive strategy of "Globalisation" and "Mid-to-High-End Premiumisation" and actively deepened cooperation with global channels, achieving strong growth in operating performance. For the first three quarters of 2026, the Company recorded total revenue of HK$95.79 billion, representing a year-on-year increase of 15.7%. Gross profit increased by 29.5% year-on-year to HK$16.26 billion, while gross profit margin increased by 1.8 percentage points year-on-year to 17.0%. The overall expense^[1] ratio was 11.9%. Driven by both improved operating efficiency and the realisation of economies of scale, adjusted profit attributable to owners of the parent increased by 54.5% year-on-year to HK$2.24 billion.

In terms of strategic development, the Company continued to advance industrial synergies, the integration of core assets and the optimisation of its business structure. On 31 March 2026 (after trading hours), the Company entered into a transaction framework agreement with Sony in relation to the home entertainment business. The two parties proposed to establish a joint venture to jointly build a new global home entertainment ecosystem, providing important strategic support for the expansion into the mid-to-high-end market. In addition, on 15 July 2026 (after trading hours), the Company announced its proposed acquisition of the TCL air-conditioning business for a total consideration of HK$5.61 billion. The transaction was completed on 2 November 2026, and the relevant business has been consolidated into the Company's financial statements since the completion date, laying an important foundation for the Company to comprehensively implement its "All-category Smart Device" strategy. On 24 August 2026, the Company announced that it was considering the spin-off and separate listing of its photovoltaic business through a distribution in specie. The Company will comprehensively and prudently evaluate the various impacts of implementing this proposal from the perspective of maximising the interests of all shareholders. Looking ahead to the full year of 2026, the Company is confident that it will achieve sustained and steady growth through firm execution of its strategies.

Continued Enhancement of Global Brand Strength, with Significant Improvements in Profitability of Mid-to-High-End and Large-Sized TVs in International Markets

Underpinned by continued enhancement of its global brand strength, efficient channel expansion and ongoing product mix optimisation, the Company's Display Business recorded revenue of HK$62.38 billion, representing a year-on-year increase of 19.1%, and gross profit of HK$11.51 billion, representing a year-on-year increase of 38.4%. Gross profit margin increased by 2.6 percentage points year-on-year to 18.5%. Benefitting from the continued increase in the proportion of mid-to-high-end and large-sized TVs, revenue from the TCL TV business increased by 16.7% year-on-year to HK$52.03 billion, while gross profit margin increased by 3.2 percentage points year-on-year to 19.5%.

TCL Mini LED TVs maintained rapid growth for the first three quarters of 2026, with global shipments increasing by 57.9% year-on-year and their share of total shipments rising by 6.1 percentage points year-on-year to 17.5%. In particular, shipments in international markets increased by 94.5% year-on-year, driving a 4.4-percentage-point year-on-year increase in the gross profit margin of the TV business in international markets to 19.0%. The Company continued to expand its global channel footprint and deepen the development of key channels. These efforts helped TCL TV rank among the top three globally in sales revenue, maintain its second-place ranking globally in shipment volume, and retain its position as the world's No. 1 brand in TCL Mini LED TV shipments^[2]. TCL X11L SQD-Mini LED TV was named one of TIME magazine's "Best Inventions of 2026" in the United States, making it the only Chinese television product selected in this category and further demonstrating the Company's leading position in premium display technology.

In the Small-and-Medium-Sized Display business, the Company adhered to the strategy of "prioritising efficiency and focusing on key markets" and continued to deepen its presence in key channels in Europe and the United States. Leveraging differentiated products such as NXTPAPER eye-care display technology, the business achieved growth against the market trend, with both revenue and gross profit outperforming the industry as a whole. For the first three quarters of 2026, revenue from the Small-and-Medium-Sized Display business increased by 32.2% year-on-year to HK$9.32 billion.

International Internet Business Contributes to High-Quality Earnings, While Photovoltaic Business Achieves Substantive Progress in the European Market

During the Reporting Period, the Company's Internet Business recorded revenue of HK$2.70 billion, representing a year-on-year increase of 28.2%. Among its businesses, the expansion of the higher-margin international internet business continued to accelerate, with its share of Internet Business revenue increasing by 17.0 percentage points year-on-year. This drove a 4.6-percentage-point year-on-year increase in the overall gross profit margin of the Internet Business to 60.9%, continuing to contribute high-quality earnings. In international markets, leveraging its scale advantages, the Company continued to deepen cooperation with internet giants such as Google, Roku and Netflix. The content application TCL Channel continued to undergo iterative upgrades in terms of content richness, user experience and monetisation efficiency. As at the end of September 2026, TCL Channel had a cumulative user base of 56.99 million.

In the Innovative Business, for the first three quarters of 2026, the Company recorded revenue of HK$30.68 billion, representing a year-on-year increase of 8.5%. Among its businesses, the Photovoltaic Business maintained resilient growth amid industry headwinds, with revenue increasing by 11.8% year-on-year to HK$18.18 billion. The business focused on key countries in Europe in international markets and made substantive progress in advancing integrated energy solutions combining photovoltaics, energy storage and heating, leveraging the brand influence of SunPower.

For the first three quarters of 2026, the Company continued to promote the synergistic development of its All-Category Marketing business and improve the layout of its smart device product portfolio. Revenue increased by 3.3% year-on-year to HK$10.95 billion. Meanwhile, in August 2026, the Company launched TCL AiMe, an AI companion and caregiving robot, further enriching its all-scenario smart ecosystem and opening up new growth opportunities in the emerging consumer electronics sector.

About TCL Electronics

TCL Electronics Holdings Limited (01070.HK, incorporated in the Cayman Islands with limited liability) has been listed on the Main Board of The Stock Exchange of Hong Kong Limited since November 1999. Its business scope covers display business, innovative business, and internet business. Guided by the business philosophy of "Strategy Guidance, Innovation Driven, Advanced Manufacturing and Global Operation", TCL Electronics actively embraces transformation and innovation and focuses on breaking into the mid-to high-end global market, and strives for an all-category layout for the "Smart IoT Ecosystem". Dedicated to providing users with all-scenario smart healthy living experiences, TCL Electronics aims to become a leading global intelligent terminal enterprise. TCL Electronics is included in the list of eligible shares for the Shenzhen-Hong Kong Stock Connect. It is a constituent stock of the Hang Seng Stock Connect Hong Kong Index, the Hang Seng Composite LargeCap & MidCap Index, the Hang Seng Composite MidCap Index and the "Hang Seng SCHK Electronics Theme Index". Since 2018, the Company has been awarded an ESG rating of A by Hang Seng Indexes Company for several consecutive years.

 For more information, please visit TCL Electronics' investor relations website at http://electronics.tcl.com.

T. Rowe Price global equity portfolio specialist Jennifer O'Hara Martin said recent market jitters and the sharp selloff in AI stocks largely reflected investors' reassessment of valuations and expectations, rather than weakening demand. She still believed demand for AI computing power and infrastructure remains strong, while industry supply continues to be tight.

The resignation of NVIDIA (NVDA.US) CEO Jensen Huang was a company-specific event rather than a fundamental change in the outlook for AI demand, she said, adding that she is more focused on how NVIDIA's organizational and decision-making structure will be adjusted, believing the transition may require a new organizational structure rather than simply appointing a new CEO.

However, she foresaw the company's established product roadmap to remain broadly unchanged. Going forward, she will keep tab on whether the pace of product development slows, potentially giving competitors more room to seize market share.
~

AASTOCKS Financial News
Website: www.aastocks.com

US President Donald Trump said former NVIDIA (NVDA.US) CEO Jensen Huang had called him and expressed remorse over the harm the scandal had caused to his family, adding that Huang was most concerned about his wife and family members.

In an interview, Trump praised Huang, saying that his achievements are incredible, and NVIDIA is simply unbelievable, adding that he believed Huang would overcome the difficulties and that he will definitely make a comeback in the end.

When asked whether Huang should resign, Trump said the key issue was whether the woman (Alice Huang) was a spy, and it was currently unclear whether her identity had been confirmed. However, if she were a spy, then Huang should resign; if she were not a spy, the situation might be different.
~

AASTOCKS Financial News
Website: www.aastocks.com

Senior White House officials are discussing whether Commerce Secretary Howard Lutnick should be replaced over a spying scandal involving former NVIDIA (NVDA.US) CEO Jensen Huang, as a growing number of lawmakers criticize Lutnick for refusing to place dozens of Chinese companies on the US critical trade blacklist and question whether the government has properly supervised NVIDIA’s exports to China, Reuters, citing sources, reported.

However, a White House official said US President Donald Trump still has full confidence in Lutnick and his ability to perform his duties.

The US government had previously suspended plans to place DeepSeek, CXMT (688825.SH), and more than 100 other companies identified as national security risks on the trade blacklist.

Multiple Democratic lawmakers wrote to Lutnick, Secretary of State Marco Rubio, and White House Chief of Staff Stephen Miller, requesting that the government preserve all documents related to NVIDIA’s exports of advanced AI chips to China and the associated national security risks.
~

AASTOCKS Financial News
Website: www.aastocks.com

Merger talks between SpaceX (SPCX.US) and Tesla (TSLA.US) are making progress and could be announced as early as December, Bloomberg, citing sources, reported . The boards and advisers of both companies are finalizing merger terms and governance arrangements for the combined entity.

However, sources said the two companies still need to overcome multiple hurdles before completing the transaction, including how to ring-fence Tesla operations in China.

The merger would become a major test of the political climate after the US midterm elections, with Democrats, who regained control of Congress, pledging to investigate Elon Musk's business and political activities.
~

AASTOCKS Financial News
Website: www.aastocks.com